On or around 11/05/2018 (Notice of voluntarily dismissal)
Filing Date: August 13, 2018
According to the Complaint, TapImmune, Inc. ("TapImmune" or the "Company") is a biotechnology company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease.
On May 15, 2018, TapImmune issued a press release announcing the Merger Agreement with Marker Therapeutics, Inc. pursuant to which, Marker shareholders will receive (i) shares of TapImmune's common stock equal to the number of shares of TapImmune common stock issued and outstanding immediately prior to the effective time of the merger, and (ii) a number of warrants equal to the number of TapImmune warrants and stock options issued and outstanding immediately prior to the effective time of the merger (the "Merger Consideration").
The Complaint alleges that on July 13, 2018, the Board authorized the filing of a materially incomplete and misleading proxy statement (the "Proxy") with the Securities and Exchange Commission ("SEC"), in violation of Sections 14(a) and 20(a) of the Exchange Act.
On November 6, 2018, this case was voluntarily dismissed as moot.
Company & Securities Information
Defendant: TapImmune, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: TPIV
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Todd Williams, et al. v. TapImmune, Inc., et al.
COURT: D. Nevada
DOCKET #: 18-CV-01497
JUDGE: Hon. Richard F. Boulware, II
DATE FILED: 08/13/2018
CLASS PERIOD START: 05/15/2018
CLASS PERIOD END: 08/13/2018
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Albright, Stoddard, Warnick & Albright 801 South Rancho Drive, Quail Park Suite D-4, Albright, Stoddard, Warnick & Albright, NV 89106 702.384.7111 ·
Monteverde & Associates PC 350 Fifth Avenue, 59th Floor, Monteverde & Associates PC, NY 10118 (212) 971-1341 ·
First Identified Complaint (FIC) Filings:
Class Action Complaint
U.S. District Court Civil Docket
—Reference Complaint Complaint Related Data is not available
Related District Court Filings
—Related District Court Filings Data is not available